Novo Nordisk remains a Buy due to its strong long-term fundamentals and leadership in obesity treatment, particularly with its Wegovy pill. Although the company faces short-term issues like declining gross margins, high capital expenditures, and a failed drug trial, its operating margins and capital management are solid. Management has improved its 2026 guidance, now expecting adjusted sales and operating profit to decline by up to 6%, better than previous forecasts. The stock trades at a valuation below its 10-year average, with confidence in a return to double-digit growth annually.
Viking Therapeutics surged 26.5% after releasing positive topline results from its GLP-1/GIP agonist VK2735 maintenance dosing study in adults with obesity. The data suggest multiple effective maintenance dosing schedules, potentially improving patie...
Novo Nordisk held its investor day in London, outlining its strategy for growth after its key obesity drugs lose patent protection. Despite plans for multiple new blockbusters and expansion into heart and liver disease treatments, analysts were unimp...
Novo Nordisk CEO Mike Doustdar revealed the company is actively considering mergers and acquisitions to strengthen its position in the competitive weight-loss drug market. He emphasized the company's interest in acquiring or partnering with firms tha...
Biotech stocks and leveraged ETFs were the biggest losers in the market, with Cue Biopharma dropping 23.7% despite positive Phase 2 clinical results. Leveraged ETFs tied to AMD, Strategy, and Novo Nordisk also saw sharp declines due to their daily-re...
Novo Nordisk's shares fell over 7% after the company announced long-term targets that failed to reassure investors about competition in the weight-loss drug market. The Danish drugmaker plans to launch multiple blockbuster drugs by 2030 and aims for ...
